Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials

Ascher-Svanum, 2008, Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia, Schizophr. Bull., 34, 1163, 10.1093/schbul/sbm134 Barnes, 1989, A rating scale for drug-induced akathisia, Br. J. Psychiatry, 154, 672, 10.1192/bjp.154.5.672 Breier, 2005, Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia, Am. J. Psychiatry, 162, 1879, 10.1176/appi.ajp.162.10.1879 Case, 2010, The heterogeneity of antipsychotic response in the treatment of schizophrenia, Psychol. Med Guy, 1976 Heinrichs, 1984, The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome, Schizophr. Bull., 10, 388, 10.1093/schbul/10.3.388 Kane, 2009, A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia, J. Clin. Psychiatry, 70, 572, 10.4088/JCP.08m04421 Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr. Bull., 13, 261, 10.1093/schbul/13.2.261 Keefe, 2006, One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia, Schizophr. Res., 81, 1, 10.1016/j.schres.2005.07.038 Kinon, 1993, Treatment of neuroleptic-resistant schizophrenic relapse, Psychopharmacol. Bull., 29, 309 Kinon, 2006, A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms, J. Clin. Psychopharmacol., 26, 157, 10.1097/01.jcp.0000204137.82298.06 Kinon, 2006, Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning, J. Clin. Psychopharmacol., 26, 453, 10.1097/01.jcp.0000236658.16286.25 Kinon, 2008, Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia, Schizophr. Res., 102, 230, 10.1016/j.schres.2008.02.021 Leucht, 2005, What does the PANSS mean?, Schizophr. Res., 79, 231, 10.1016/j.schres.2005.04.008 Leucht, 2007, Defining ‘response’ in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs, Neuropsychopharmacology, 32, 1903, 10.1038/sj.npp.1301325 Levine, 2010, Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories, Biol. Psychiatry, 68, 86, 10.1016/j.biopsych.2010.01.012 Levine, 2010, Trajectories and antecedents of treatment response over time in early-episode psychosis, Schizophr. Bull., 36, 624, 10.1093/schbul/sbn120 Levine, 2010, Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study, J. Clin. Psychopharmacol., 30, 446, 10.1097/JCP.0b013e3181e68e80 Levine, 2010, Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades, Schizophr. Res., 126, 184 Lieberman, 2003, Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol, Am. J. Psychiatry, 160, 1396, 10.1176/appi.ajp.160.8.1396 Marques, 2010, The different trajectories of antipsychotic response: antipsychotics versus placebo, Psychol. Med Montgomery, 1979, A new depression scale designed to be sensitive to change, Br. J. Psychiatry, 134, 382, 10.1192/bjp.134.4.382 Muthén, 2007 Muthén, 1999, Finite mixture modeling with mixture outcomes using the EM algorithm, Biometrics, 55, 463, 10.1111/j.0006-341X.1999.00463.x Muthén, 2002, General growth mixture modeling for randomized preventive interventions, Biostatistics, 3, 459, 10.1093/biostatistics/3.4.459 Simpson, 1970, A rating scale for extrapyramidal side effects, Acta Psychiatr. Scand. Suppl., 212, 11, 10.1111/j.1600-0447.1970.tb02066.x Tran, 1997, Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders, J. Clin. Psychopharmacol., 17, 407, 10.1097/00004714-199710000-00010 World Health Organization Statistics on Schizophrenia